Adenosine and anergy

Autoimmunity

Volumn 40, Issue 6, 2007, Pages 425-432

  Zarek, Paul E ^a   Powell, Jonathan D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenosine; Adenosine A2A receptor; Anergy; T cell; Tolerance

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; B7 ANTIGEN; CD28 ANTIGEN; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EARLY GROWTH RESPONSE FACTOR 2; EARLY GROWTH RESPONSE FACTOR 3; GAMMA INTERFERON; HISTONE DEACETYLASE; INTERLEUKIN 10; INTERLEUKIN 2; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOLIPASE C GAMMA; RAP1 PROTEIN; T LYMPHOCYTE RECEPTOR; TACROLIMUS; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NFAT; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ANTIGEN RECOGNITION; ARTHRITIS; AUTOIMMUNITY; CLONAL ANERGY; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG POTENCY; ENTERITIS; ENZYME ACTIVATION; ENZYME DEGRADATION; GENE CONTROL; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; KIDNEY DISEASE; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PROMOTER REGION; PROTEIN FUNCTION; REPERFUSION INJURY; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ADENOSINE; ANIMALS; AUTOIMMUNITY; HUMANS; IMMUNE TOLERANCE; RECEPTORS, ADENOSINE A2; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 34548313704     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930701464939     Document Type: Review

References (79)

1. Fredholm, BB, Ap, Ij, Jacobson, KA, Klotz, KN and Linden, J. (2001) International union of pharmacology XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev, 53:4, pp. 527-552.
2. Ohta, A. and Sitkovsky, M. (2001) Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature, 414:6866, pp. 916-920.
3. Lappas, CM, Rieger, JM and Linden, J. (2005) A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+T cells. J Immunol, 174:2, pp. 1073-1080.
4. Erdmann, AA, Gao, ZG, Jung, U., Foley, J., Borenstein, T., Jacobson, KA and Fowler, DH (2005) Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. Blood, 105:12, pp. 4707-4714.
5. Lukashev, D., Ohta, A., Apasov, S., Chen, JF and Sitkovsky, M. (2004) Cutting edge: Physiologic attenuation of proinflammatory transcription by the G(s) protein-coupled A2A adenosine receptor in vivo. J Immunol, 173:1, pp. 21-24.
6. Powell, JD (2006) The induction and maintenance of T cell anergy. Clin Immunol, 120:3, pp. 239-246.
7. Jenkins, MK and Schwartz, RH (1987) Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med, 165:2, pp. 302-319.
8. Lerner, CG, Horton, MR, Schwartz, RH and Powell, JD (2000) Distinct requirements for C-C chemokine and IL-2 production by naive, previously activated, and anergic T cells. J Immunol, 164:8, pp. 3996-4002.
9. Chen, L., Rao, A. and Harrison, SC (1999) Signal integration by transcription-factor assemblies: Interactions of NF-AT1 and AP-1 on the IL-2 promoter. Cold Spring Harb Symp Quant Biol, 64, pp. 527-531.
10. Macian, F., Garcia-Cozar, F., Im, SH, Horton, HF, Byrne, MC and Rao, A. (2002) Transcriptional mechanisms underlying lymphocyte tolerance. Cell, 109:6, pp. 719-731.
11. Jenkins, MK, Chen, CA, Jung, G., Mueller, DL and Schwartz, RH (1990) Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. J Immunol, 144:1, pp. 16-22.
12. Kowalski, J., Drake, C., Schwartz, RH and Powell, J. (2004) Non-parametric, hypothesis-based analysis of microarrays for comparison of several phenotypes. Bioinformatics, 20:3, pp. 364-373.
13. Safford, M., Collins, S., Lutz, MA, Allen, A., Huang, CT, Kowalski, J., Blackford, A., Horton, MR, Drake, C. and Schwartz, RH (2005) Egr-2 and Egr-3 are negative regulators of T cell activation. Nat Immunol, 6:5, pp. 472-480.
14. Anderson, PO, Manzo, BA, Sundstedt, A., Minaee, S., Symonds, A., Khalid, S., Rodriguez-Cabezas, ME, Nicolson, K. and Wraith, DC (2006) Persistent antigenic stimulation alters the transcription program in T cells, resulting in antigen-specific tolerance. Eur J Immunol, 36:6, pp. 1374-1385.
15. Harris, JE, Bishop, KD, Phillips, NE, Mordes, JP, Greiner, DL, Rossini, AA and Czech, MP (2004) Early growth response gene-2, a zinc-finger transcription factor, is required for full induction of clonal anergy in CD4+T cells. J Immunol, 173:12, pp. 7331-7338.
16. Heissmeyer, V., Macian, F., Im, SH, Varma, R., Feske, S., Venuprasad, K., Liu, YC, Dustin, ML and Rao, A. (2004) Calcineurin imposes T cell unresponsiveness through targeted proteolysis of signalling proteins. Nat Immunol, 5:3, pp. 255-265.
17. Anandasabapathy, N., Ford, GS, Bloom, D., Holness, C., Paragas, V., Seroogy, C., Skrenta, H., Hollenhorst, M., Fathman, CG and Soares, L. (2003) GRAIL: An E3 ubiquitin ligase that inhibits cytokine gene transcription is expressed in anergic CD4+T cells. Immunity, 18:4, pp. 535-547.
18. Jeon, MS, Atfield, A., Venuprasad, K., Krawczyk, C., Sarao, R., Elly, C., Yang, C., Arya, S. and Bachmaier, K. (2004) Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity, 21:2, pp. 167-177.
19. Seroogy, CM, Soares, L., Ranheim, EA, Holness, C., Bloom, D. and Fathman, CG (2004) The gene related to anergy in lymphocytes, an E3 ubiquitin ligase, is necessary for anergy induction in CD4 T cells. J Immunol, 173:1, pp. 79-85.
20. Mueller, DL (2004) E3 ubiquitin ligases as T cell anergy factors. Nat Immunol, 5:9, pp. 883-890.
21. Whaley, CD, Mondino, A. and Mueller, DL (1996) Blocked signal transduction to the ERK and JNK protein kinases in anergic CD4+T cells. Science, 271:5253, pp. 1272-1276.
22. Fields, PE, Gajewski, TF and Fitch, FW (1996) Blocked Ras activation in anergic CD4+T cells. Science, 271:5253, pp. 1276-1278.
23. Boussiotis, VA, Freeman, GJ, Berezovskaya, A., Barber, DL and Nadler, LM (1997) Maintenance of human T cell anergy: Blocking of IL-2 gene transcription by activated Rap1. Science, 278:5335, pp. 124-128.
24. Greenwald, RJ, Lafuente, EM, Tzachanis, D., Berezovskaya, A., Freeman, GJ, Sharpe, AH and Boussiotis, VA (2005) Rap1-GTP is a negative regulator of Th cell function and promotes the generation of CD4+CD103+ regulatory T cells in vivo. J Immunol, 175:5, pp. 3133-3139.
25. Zha, Y., Marks, R., Ho, AW, Peterson, AC, Janardhan, S., Brown, I., Praveen, K., Stang, S., Stone, JC and Gajewski, TF (2006) T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha. Nat Immunol, 7:11, pp. 1166-1173.
26. Olenchock, BA, Guo, R., Carpenter, JH, Jordan, M., Topham, MK, Koretzky, GA and Zhong, XP (2006) Disruption of diacylglycerol metabolism impairs the induction of T cell anergy. Nat Immunol, 7:11, pp. 1174-1181.
27. Powell, JD, Lerner, CG, Ewoldt, GR and Schwartz, RH (1999) The - 180 site of the IL-2 promoter is the target of CREB/CREM binding in T cell anergy. J Immunol, 163:12, pp. 6631-6639.
28. Telander, DG, Malvey, EN and Mueller, DL (1999) Evidence for repression of IL-2 gene activation in anergic T cells. J Immunol, 162:3, pp. 1460-1465.
29. Tenbrock, K., Juang, YT, Tolnay, M. and Tsokos, GC (2003) The cyclic adenosine 5'-monophosphate response element modulator suppresses IL-2 production in stimulated T cells by a chromatin-dependent mechanism. J Immunol, 170:6, pp. 2971-2976.
30. Solomou, EE, Juang, YT and Tsokos, GC (2001) Protein kinase C-theta participates in the activation of cyclic AMP-responsive element-binding protein and its subsequent binding to the - 180 site of the IL-2 promoter in normal human T lymphocytes. J Immunol, 166:9, pp. 5665-5674.
31. Bandyopadhyay, S., Dure, M., Paroder, M., Soto-Nieves, N., Puga, I. and Macian, F. (2006) Interleukin 2 gene transcription is regulated by Ikaros-induced changes in histone acetylation in anergic T cells. Blood
32. Thomas, RM, Gao, L. and Wells, AD (2005) Signals from CD28 induce stable epigenetic modification of the IL-2 promoter. J Immunol, 174:8, pp. 4639-4646.
33. Perez, VL, Van Parijs, L., Biuckians, A., Zheng, XX, Strom, TB and Abbas, AK (1997) Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity, 6:4, pp. 411-417.
34. Adler, AJ, Huang, CT, Yochum, GS, Marsh, DW and Pardoll, DM (2000) In vivo CD4+T cell tolerance induction versus priming is independent of the rate and number of cell divisions. J Immunol, 164:2, pp. 649-655.
35. Rocha, B., Tanchot, C. and Von Boehmer, H. (1993) Clonal anergy blocks in vivo growth of mature T cells and can be reversed in the absence of antigen. J Exp Med, 177:5, pp. 1517-1521.
36. Rocha, B., Grandien, A. and Freitas, AA (1995) Anergy and exhaustion are independent mechanisms of peripheral T cell tolerance. J Exp Med, 181:3, pp. 993-1003.
37. Staveley-O'Carroll, K., Sotomayor, E., Montgomery, J., Borrello, I., Hwang, L., Fein, S., Pardoll, D. and Levitsky, H. (1998) Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci USA, 95:3, pp. 1178-1183.
38. Greenwald, RJ, Boussiotis, VA, Lorsbach, RB, Abbas, AK and Sharpe, AH (2001) CTLA-4 regulates induction of anergy in vivo. Immunity, 14:2, pp. 145-155.
39. Pape, KA, Kearney, ER, Khoruts, A., Mondino, A., Merica, R., Chen, ZM, Ingulli, E., White, J., Johnson, JG and Jenkins, MK (1997) Use of adoptive transfer of T cell-antigen-receptor-transgenic T cell for the study of T cell activation in vivo. Immunol Rev, 156, pp. 67-78.
40. Huang, CT, Huso, DL, Wang, T., Zhou, G., Kennedy, EP, Drake, CG, Morgan, DJ, Sherman, LA and Higgins, AD (2003) CD4+T cells pass through an effector phase during the process of in vivo tolerance induction. J Immunol, 170:8, pp. 3945-3953.
41. Andris, F., Denanglaire, S., de Mattia, F., Urbain, J. and Leo, O. (2004) Naive T cells are resistant to anergy induction by anti-CD3 antibodies. J Immunol, 173:5, pp. 3201-3208.
42. Hayashi, RJ, Loh, DY, Kanagawa, O. and Wang, F. (1998) Differences between responses of naive and activated T cells to anergy induction [in process citation]. J Immunol, 160:1, pp. 33-38.
43. Schwartz, RH (2003) T cell anergy. Annu Rev Immunol, 21, pp. 305-334.
44. Medzhitov, R. and Janeway Jr, CA (2000) How does the immune system distinguish self from nonself?. Semin Immunol, 12:3, pp. 185-188.
45. Fuchs, EJ and Matzinger, P. (1996) Is cancer dangerous to the immune system?. Semin Immunol, 8:5, pp. 271-280.
46. Shi, Y., Evans, JE and Rock, KL (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature, 425:6957, pp. 516-521.
47. Andersson, U., Wang, H., Palmblad, K., Aveberger, AC, Bloom, O., Erlandsson-Harris, H., Janson, A., Kokkola, R., Zhang, M. and Yang, H. (2000) High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med, 192:4, pp. 565-570.
48. Powell, JD and Horton, MR (2005) Threat matrix: Low-molecular-weight hyaluronan (HA) as a danger signal. Immunol Res, 31:3, pp. 207-218.
49. Zheng, Y., Collins, SL, Lutz, MA, Allen, AN, Kole, TP, Zarek, PE and Powell, JD (2007) A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J Immunol, 178:4, pp. 2163-2170.
50. Hay, N. and Sonenberg, N. (2004) Upstream and downstream of mTOR. Genes Dev, 18:16, pp. 1926-1945.
51. Powell, JD, Lerner, CG and Schwartz, RH (1999) Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol, 162:5, pp. 2775-2784.
52. Vanasek, TL, Khoruts, A., Zell, T. and Mueller, DL (2001) Antagonistic roles for CTLA-4 and the mammalian target of rapamycin in the regulation of clonal anergy: Enhanced cell cycle progression promotes recall antigen responsiveness. J Immunol, 167:10, pp. 5636-5644.
53. Allen, A., Zheng, Y., Gardner, L., Safford, M., Horton, MR and Powell, JD (2004) The novel cyclophilin binding compound, sanglifehrin A, disassociates G1 cell cycle arrest from tolerance induction. J Immunol, 172:8, pp. 4797-4803.
54. Zimmermann, H. (2000) Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch Pharmacol, 362:4, pp. 299-309.
55. Williams, TC and Jarvis, SM (1991) Multiple sodium-dependent nucleoside transport systems in bovine renal brush-border membrane vesicles. Biochem J, 274, pp. 27-33.
56. Berne, RM and Rubio, R. (1974) Adenine nucleotide metabolism in the heart. Circ Res, 35, pp. 109-120.
57. Latini, S., Bordoni, F., Pedata, F. and Corradetti, R. (1999) Extracellular adenosine concentrations during in vitro ischaemia in rat hippocampal slices. Br J Pharmacol, 127:3, pp. 729-739.
58. Latini, S., Bordoni, F., Corradetti, R., Pepeu, G. and Pedata, F. (1999) Effect of A2A adenosine receptor stimulation and antagonism on synaptic depression induced by in vitro ischaemia in rat hippocampal slices. Br J Pharmacol, 128:5, pp. 1035-1044.
59. Lloyd, HG and Fredholm, BB (1995) Involvement of adenosine deaminase and adenosine kinase in regulating extracellular adenosine concentration in rat hippocampal slices. Neurochem Int, 26:4, pp. 387-395.
60. Blay, J., White, TD and Hoskin, DW (1997) The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res, 57:13, pp. 2602-2605.
61. Cronstein, BN, Kramer, SB, Weissmann, G. and Hirschhorn, R. (1983) Adenosine: A physiological modulator of superoxide anion generation by human neutrophils. J Exp Med, 158:4, pp. 1160-1177.
62. Cronstein, BN (1994) Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol, 76:1, pp. 5-13.
63. Cronstein, BN, Levin, RI, Belanoff, J., Weissmann, G. and Hirschhorn, R. (1986) Adenosine: An endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest, 78:3, pp. 760-770.
64. Newby, AC, Holmquist, CA, Illingworth, J. and Pearson, JD (1983) The control of adenosine concentration in polymorphonuclear leucocytes, cultured heart cells and isolated perfused heart from the rat. Biochem J, 214:2, pp. 317-323.
65. Leonard, EJ, Shenai, A. and Skeel, A. (1987) Dynamics of chemotactic peptide-induced superoxide generation by human monocytes. Inflammation, 11:2, pp. 229-240.
66. Salmon, JE, Brogle, N., Brownlie, C., Edberg, JC, Kimberly, RP, Chen, BX and Erlanger, BF (1993) Human mononuclear phagocytes express adenosine A1 receptors. A novel mechanism for differential regulation of Fc gamma receptor function. J Immunol, 151:5, pp. 2775-2785.
67. Lappin, D. and Whaley, K. (1984) Adenosine A2 receptors on human monocytes modulate C2 production. Clin Exp Immunol, 57:2, pp. 454-460.
68. Parmely, MJ, Zhou, WW, Edwards 3rd, CK, Borcherding, DR, Silverstein, R. and Morrison, DC (1993) Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-alpha production and protect mice against endotoxin challenge. J Immunol, 151:1, pp. 389-396.
69. Jordan, JE, Zhao, ZQ, Sato, H., Taft, S. and Vinten-Johansen, J. (1997) Adenosine A2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. J Pharmacol Exp Ther, 280:1, pp. 301-309.
70. Ross, SD, Tribble, CG, Linden, J., Gangemi, JJ, Lanpher, BC, Wang, AY and Kron, IL (1999) Selective adenosine-A2A activation reduces lung reperfusion injury following transplantation. J Heart Lung Transplant, 18:10, pp. 994-1002.
71. Montesinos, MC, Desai, A., Delano, D., Chen, JF, Fink, JS, Jacobson, MA and Cronstein, BN (2003) Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum, 48:1, pp. 240-247.
72. Okusa, MD (2002) A(2A) adenosine receptor: A novel therapeutic target in renal disease. Am J Physiol Renal Physiol, 282:1, pp. F10-F18.
73. Odashima, M., Bamias, G., Rivera-Nieves, J., Linden, J., Nast, CC, Moskaluk, CA, Marini, M., Sugawara, K., Kozaiwa, K. and Otaka, M. (2005) Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. Gastroenterology, 129:1, pp. 26-33.
74. Lappas, CM, Day, YJ, Marshall, MA, Engelhard, VH and Linden, J. (2006) Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J Exp Med, 203:12, pp. 2639-2648.
75. Filippini, A., Taffs, RE and Sitkovsky, MV (1990) Extracellular ATP in T-lymphocyte activation: Possible role in effector functions. Proc Natl Acad Sci USA, 87:21, pp. 8267-8271.
76. Apasov, SG, Koshiba, M., Chused, TM and Sitkovsky, MV (1997) Effects of extracellular ATP and adenosine on different thymocyte subsets: Possible role of ATP-gated channels and G protein-coupled purinergic receptor. J Immunol, 158:11, pp. 5095-5105.
77. Huang, S., Apasov, S., Koshiba, M. and Sitkovsky, M. (1997) Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T cell activation and expansion. Blood, 90:4, pp. 1600-1610.
78. Sitkovsky, MV, Lukashev, D., Apasov, S., Kojima, H., Koshiba, M., Caldwell, C., Ohta, A. and Thiel, M. (2004) Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors*. Annu Rev Immunol, 22, pp. 657-682.
79. Heath, WR and Carbone, FR (2003) Immunology: Dangerous liaisons. Nature, 425:6957, pp. 460-461.